Subclinical TB With Innovative Modified Short-course Regimens - Trial NCT06153069
Access comprehensive clinical trial information for NCT06153069 through Pure Global AI's free database. This Phase 4 trial is sponsored by Huashan Hospital and is currently Recruitment Completed. The study focuses on Tuberculosis. Target enrollment is 556 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Huashan Hospital
Timeline & Enrollment
Phase 4
Nov 01, 2023
Nov 01, 2027
Primary Outcome
Treatment success rate of the short-course regimen
Summary
This study is a randomized controlled trial among subclinical tuberculosis patients aiming to
 assess whether the standard treatment duration can be shortened to 17 weeks or even 8 weeks
 without changing the current anti-tuberculosis drugs or dosages.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06153069
Non-Device Trial